LIGAND PHARMACEUTICALS INCORPORATED Payments for Derivative Instrument, Financing Activities
LIGAND PHARMACEUTICALS INCORPORATED (LGNYZ) reported Payments for Derivative Instrument, Financing Activities of $195.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForDerivativeInstrumentFinancingActivities · last filed 2026-08-07
- LIGAND PHARMACEUTICALS INCORPORATED payments for derivative instrument, financing activities for the quarter ending 2025-12-31 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED payments for derivative instrument, financing activities for the quarter ending 2025-09-30 was $113.25M.
- LIGAND PHARMACEUTICALS INCORPORATED payments for derivative instrument, financing activities for the quarter ending 2024-12-31 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED payments for derivative instrument, financing activities for fiscal 2025 was $113.25M.
- LIGAND PHARMACEUTICALS INCORPORATED payments for derivative instrument, financing activities for fiscal 2024 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED payments for derivative instrument, financing activities for fiscal 2023 was $0.00.
| Period end | Payments for Derivative Instrument, Financing Activities 3 month | Payments for Derivative Instrument, Financing Activities 6 month | Payments for Derivative Instrument, Financing Activities 9 month | Payments for Derivative Instrument, Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $195.79M 10-Q · filed 2026-08-07 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $113.25M derived: sum of 2 quarters · filed 2026-02-27 | $113.25M 10-K · filed 2026-02-27 | |
| 2025-09-30 | $113.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $113.25M 10-Q · filed 2025-11-07 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-07 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-07 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-27 |